Pharma

Your Article Summary

See Latest Articles

Study Showed VYVANSE (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Shire, 07/02/09

Shire plc, the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder. VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New Clinical Drug Evaluation Unit meeting in Hollywood, FL. VYVANSE is currently approved by the US Food and Drug Administration for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09

GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09

Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
BayNews International, 12/02/09

 See all of Research & Development